Oasmia Pharmaceutical AB, a developer of a new generation of drugs
within human and veterinary oncology, announced today the topline
findings from a head-to-head comparison study of its lead human cancer
product Paclical and Celgene's Abraxane ,which show similar pharmacokinetic (PK) profiles. The study was conducted in women with metastatic breast cancer.
"We believe our technology is superior to that of Abraxane
because it increases the solubility of paclitaxel in water," commented
Margareta Eriksson, Vice President of Clinical Development at Oasmia
Pharmaceutical. "The benefits of using our treatment over those
currently available on the market are simple: Paclical
enables higher doses, shortens infusion time, eliminates the need for
pre-medication and improves the safety profile for patients."
No comments:
Post a Comment